Ipamorelinとは？研究概要

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that stimulates the pulsatile release of growth hormone (GH) from the anterior pituitary gland by binding to the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. What distinguishes ipamorelin from earlier growth hormone-releasing peptides like GHRP-6 and GHRP-2 is its remarkable selectivity: it stimulates GH release without causing significant increases in cortisol, ACTH, prolactin, or aldosterone, which are common side effects of less selective GH secretagogues. This selectivity has made ipamorelin one of the most widely studied peptides in growth hormone research.

Developed in the mid-1990s by Novo Nordisk, ipamorelin's five-amino-acid sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) was designed through systematic structure-activity relationship studies to maximize GH-releasing potency while minimizing off-target hormonal effects. The compound demonstrated that it was possible to create a ghrelin receptor agonist with a much cleaner pharmacological profile than its predecessors, which often triggered hunger, cortisol spikes, and other unwanted effects.

How Does Ipamorelin Work?

Ipamorelin works by binding to GHSR-1a receptors on somatotroph cells in the anterior pituitary gland. This receptor binding triggers a signaling cascade involving increased intracellular calcium, which stimulates the fusion of GH-containing secretory granules with the cell membrane and the subsequent release of GH into the bloodstream. Importantly, ipamorelin amplifies the natural pulsatile pattern of GH release rather than creating a constant, non-physiological elevation — a key advantage over exogenous GH administration.

The selectivity of ipamorelin appears to stem from its receptor-binding kinetics and its lack of significant activity at other pituitary receptor subtypes. While GHRP-6, for example, also activates receptors that stimulate ACTH and cortisol release, ipamorelin's binding profile is more constrained to the GH-release pathway. Research has shown that even at doses 200 times the effective GH-releasing dose, ipamorelin does not significantly stimulate cortisol or ACTH release — a selectivity profile not observed with other GH secretagogues.

Once GH is released, it acts on the liver to stimulate insulin-like growth factor 1 (IGF-1) production, which mediates many of GH's downstream effects on protein synthesis, cell growth, fat metabolism, and tissue repair. Ipamorelin's preservation of normal GH pulsatility means IGF-1 responses also follow a more physiological pattern.

Key Research Findings

Study Focus	Model	Key Finding	Year
Selectivity profile	Swine	Stimulated GH release with no significant cortisol, ACTH, or prolactin elevation	1998
Bone growth	Rat	Increased bone mineral content and longitudinal bone growth in female rats	2000
Post-operative ileus	Human (Phase 2)	Accelerated GI recovery following abdominal surgery	2007
Body composition	Rat (aged)	Improved lean mass to fat mass ratio with chronic administration	2009
GH pulsatility	Human	Maintained natural GH pulse pattern while increasing overall GH output	2011

Common Research Applications

• Growth hormone optimization: Ipamorelin is studied as a means to augment declining GH levels, particularly in aging research contexts, while preserving physiological pulsatility.
• Body composition research: Studies examine ipamorelin's effects on fat reduction and lean mass preservation, mediated through GH and IGF-1 pathways.
• Bone density and growth: Preclinical research has explored ipamorelin's effects on bone mineral density and longitudinal bone growth.
• Post-surgical recovery: Clinical studies have investigated ipamorelin for post-operative gastrointestinal recovery, particularly after abdominal surgery.
• Combination protocols: Ipamorelin is frequently studied in combination with growth hormone-releasing hormone (GHRH) analogs like CJC-1295, as the two compounds synergistically amplify GH release through complementary receptor pathways.

How Does Ipamorelin Compare?

Ipamorelin is often compared to other GH secretagogues like GHRP-6 and GHRP-2. Its primary advantage is selectivity — it stimulates GH without the hunger (GHRP-6), cortisol elevation, or prolactin increases seen with less selective alternatives. For a detailed comparison with GHRP-6, see our ipamorelin vs. GHRP-6 comparison. When combined with the GHRH analog CJC-1295, the two peptides produce synergistic GH release — ipamorelin amplifies the pulse amplitude while CJC-1295 increases the pulse frequency. Explore this combination in our CJC-1295 + ipamorelin research article.

Safety and Considerations

Ipamorelin has demonstrated one of the most favorable safety profiles among GH secretagogues in preclinical and early clinical research. Its selectivity means it avoids the cortisol, ACTH, and prolactin elevations that complicate other compounds in this class. Phase 2 clinical trials investigating ipamorelin for post-operative ileus reported generally mild adverse effects. However, comprehensive long-term human safety data is limited, and ipamorelin has not received regulatory approval for any therapeutic indication. As with all GH-stimulating compounds, theoretical considerations include the potential effects of elevated GH/IGF-1 on glucose metabolism and cellular proliferation. This information is for educational and research purposes only and does not constitute medical advice.

Frequently Asked Questions

Why is ipamorelin considered the most selective GH secretagogue?

Studies have shown that ipamorelin does not significantly increase cortisol, ACTH, prolactin, or aldosterone — even at doses far exceeding those needed for GH release. This selectivity profile is unique among GH secretagogues and is attributed to ipamorelin's highly specific binding interaction with the GHSR-1a receptor, without activating the broader neuroendocrine pathways triggered by other ghrelin mimetics.

How does ipamorelin differ from exogenous growth hormone?

Exogenous GH provides a direct, non-pulsatile dose of growth hormone that bypasses the pituitary gland entirely. Ipamorelin, by contrast, stimulates the pituitary to release its own GH stores in a pulsatile, physiological pattern. This means ipamorelin works with the body's natural feedback mechanisms, which helps maintain normal GH regulation and may reduce the risk of side effects associated with supraphysiological GH levels.

Why is ipamorelin often combined with CJC-1295?

Ipamorelin (a GHSR agonist) and CJC-1295 (a GHRH analog) work through different receptor systems. GHRH increases GH release by acting on the GHRH receptor, while ipamorelin amplifies this release through the ghrelin receptor. When administered together, they produce a synergistic effect — higher peak GH levels than either compound alone — because they stimulate two complementary pathways simultaneously.